Clinical aspects of a phase I study of PD-0325901, a selective oral MEK inhibitor, in patients with advanced cancer
Year: 2007
Type: article
Study design: Clinical Trial
Source: Molecular Cancer Therapeutics
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2514915228